SYS6051 obtains clinical trial approval in the U.S.

CAR-T Digest - August 2020

29 April 2026: SYS6051 obtains clinical trial approval in the U.S.

CSPC Pharmaceutical Group announced that the U.S. FDA has approved the Investigational New Drug application for its antibody drug conjugate SYS6051, enabling the initiation of clinical trials in the United States
This milestone follows recent approval from China’s National Medical Products Administration in April 2026, allowing the program to advance into clinical development in both the U.S. and China simultaneously
SYS6051 is a tissue factor-targeted ADC designed to bind to tumor cells expressing TF, undergo internalization, and release a cytotoxic payload to selectively kill cancer cells, with development focused on advanced solid tumors
Preclinical studies have demonstrated promising anti-tumor activity across multiple cancer types, supporting its progression into clinical evaluation
With regulatory clearances now secured in two major markets, CSPC is advancing SYS6051 as part of its growing ADC pipeline aimed at delivering targeted therapies for patients with advanced malignancies